Adoptive immunotherapy with virus-specific T cells

Viral infections are still common causes of morbidity and mortality in immunosuppressed patients after allogeneic hematopoietic stem cell transplantation. Infections caused by virus such as cytomegalovirus, adenovirus and Epstein–Barr virus are well-known. In addition, several other viruses such as...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical haematology 2011-09, Vol.24 (3), p.413-419
Main Authors: Fuji, Shigeo, MD, Kapp, Markus, MD, Grigoleit, Götz Ulrich, MD, Einsele, Hermann, MD, Prof
Format: Article
Language:English
Subjects:
adoptive immunotherapy
cytokine secretion assay
Female
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation
Humans
Immunity, Cellular - immunology
Immunocompromised Host - immunology
Immunotherapy, Adoptive - methods
Male
streptamer
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Transplantation, Homologous
Virus Diseases - immunology
Virus Diseases - therapy
Virus Diseases - virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Viral infections are still common causes of morbidity and mortality in immunosuppressed patients after allogeneic hematopoietic stem cell transplantation. Infections caused by virus such as cytomegalovirus, adenovirus and Epstein–Barr virus are well-known. In addition, several other viruses such as polyomavirus and human herpesvirus 6 have been recently reported to be causes of significant complications. As the delay in recovery of virus-specific cellular immune response after transplant is associated with viral reactivation and viral disease, adoptive immunotherapy to restore virus-specific cellular immunity is an attractive option. Recent clinical trials showed the safety and effectiveness of adoptive immunotherapy against viral diseases. In this review, we summarize the current status of adoptive immunotherapy against several viral diseases including cytomegalovirus, adenovirus, Epstein–Barr virus and polyomavirus.
ISSN:1521-6926
1532-1924
DOI:10.1016/j.beha.2011.06.003